胍法辛用于治疗儿童和青少年注意力缺陷多动障碍。
Guanfacine for the treatment of attention deficit hyperactivity disorder in children and adolescents.
作者信息
Rizzo Renata, Martino Davide
机构信息
Neuropsichiatria Infantile, Dipartimento di Scienze Mediche e Pediatriche, Università di Catania, Via S. Sofia 78, 95123 Catania, Italia.
出版信息
Expert Rev Neurother. 2015 Apr;15(4):347-54. doi: 10.1586/14737175.2015.1028370.
Guanfacine is an α2A-adrenoreceptor agonist currently indicated for the treatment of attention deficit hyperactivity disorder (ADHD). This article reviews the chemistry, pharmacodynamics and pharmacokinetics of guanfacine, as well as the clinical trial literature on guanfacine for the treatment of ADHD in children and adolescents, mainly focusing on the use of guanfacine extended-release (GXR). Six already published prospective randomized controlled trials (RCTs) and one unpublished RCT study were identified for GXR in the treatment of ADHD. All RCTs trials showed superiority over placebo on the primary outcome measure. Guanfacine, especially XR, seems to be an effective and safe treatment option for ADHD in children and adolescents.
胍法辛是一种α2A肾上腺素能受体激动剂，目前被用于治疗注意力缺陷多动障碍（ADHD）。本文综述了胍法辛的化学性质、药效学和药代动力学，以及关于胍法辛治疗儿童和青少年ADHD的临床试验文献，主要聚焦于缓释胍法辛（GXR）的应用。已确定六项已发表的前瞻性随机对照试验（RCT）和一项未发表的RCT研究涉及GXR治疗ADHD。所有RCT试验在主要结局指标上均显示优于安慰剂。胍法辛，尤其是缓释剂型，似乎是治疗儿童和青少年ADHD的一种有效且安全的选择。
Zotero 插件